This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Stocks Up on Signs of Slowdown in Coronavirus Cases
by Zacks Equity Research
Coronavirus shows signs of slowdown in the United States and some other countries. While investors look for positive developments in the stock market, here are five must-buy stocks poised to grow.
Top Ranked Momentum Stocks to Buy for April 7th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 7th
Top Ranked Momentum Stocks to Buy for March 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 26th
Top Ranked Momentum Stocks to Buy for March 25th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 25th
Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SMMT) Outperforming Other Medical Stocks This Year?
Summit Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Summit Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Can the Rally in Summit Therapeutics Shares Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Summit Therapeutics.
Top Ranked Momentum Stocks to Buy for October 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 22nd
Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply
by Zacks Equity Research
Sarepta (SRPT) inks long-term strategic deal with Aldevron for the supply of plasmid DNA to fulfill the former's needs for its gene-therapy clinical trials and commercial supply.
New Strong Sell Stocks for December 19th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Catalent (CTLT) Catches Eye: Stock Jumps 5.2%
by Zacks Equity Research
Catalent (CTLT) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Zogenix's Epilepsy Candidate Successful in Phase III Study
by Zacks Equity Research
Zogenix's (ZGNX) shares rally after successful completion of confirmatory phase III study of ZX008 for treating Dravet syndrome.
Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.8%
by Zacks Equity Research
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
KemPharm Stock Down Despite Positive Data on ADHD Candidate
by Zacks Equity Research
KemPharm (KMPH) presents positive top-line results on ADHD candidate KP415, which meets both primary and secondary endpoints in a pivotal study.
Summit Therapeutics Enters Oversold Territory
by Zacks Equity Research
Summit Therapeutics Enters Oversold Territory
What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?
by Zacks Equity Research
Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.
M&A, Innovation & New Drugs to Drive Pharma Stocks
by Zacks Equity Research
The new tax law, which cuts the corporate tax rate from 35% to 21% and encourages companies to bring back cash held overseas at a one-time tax rate of 10%, is expected to spur merger activity.
Apricus Biosciences (APRI) Soars: Stock Adds 8.6% in Session
by Zacks Equity Research
Shares of Apricus Biosciences (APRI) rose about 9% yesterday.
Sarepta's Golodirsen Positive in DMD Study, Shares Soar
by Zacks Equity Research
Sarepta's (SRPT) Duchenne Muscular Dystrophy candidate, Golodirsen, achieved positive muscle biopsy results in first in-human study. Shares surged in response.
Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) announces private offering of exchangeable senior notes to qualified institutional buyers to raise proceeds and repay debt.
Perrigo (PRGO) Q2 Earnings & Sales Top, 2017 View Raised
by Zacks Equity Research
Perrigo (PRGO) posts better-than-expected results with revenue beating estimates. The company also ups its earnings outlook, courtesy a continued positive execution across all business segments.
Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact
by Zacks Equity Research
Jazz Pharma's (JAZZ) earnings and revenues miss estimates. However, the top line rises year over year owing to higher sales of the company's marketed drug, Xyrem.
Orexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress
by Zacks Equity Research
Orexigen Therapeutics (OREX) reported adjusted loss of $1.82 per share in the second quarter of 2017, which was narrower than the Zacks Consensus Estimate. The company is focused on increasing the reach of Contrave.
Endocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss
by Zacks Equity Research
Endocyte (ECYT) second quarter loss was wider than expected. The company has announced restructuring initiatives to shift its pipeline focus to CAR-T cell platform.
Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update
by Zacks Equity Research
Achillion Pharmaceuticals (ACHN) second-quarter loss was in-line with estimates. The company's shares surged almost 28% in after-market trading on positive pipeline results.